ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

PLRX vs HRTX // RSI-14 & 200D SMA MOMENTUM

Pliant Therapeutics Inc. (NASDAQ) VS. Heron Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: PLRX 1 — HRTX 1
▲ RSI-14 & 200D SMA MOMENTUM LEADER: HRTX
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PLRX VS. HRTX) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC PLRX HRTX SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 73.30% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin — -1.60% — TIE /operating-margins <GO>
Net Profit Margin — -12.90% — TIE /net-margins <GO>
Revenue Growth (YoY) — — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 2/9 0.00 TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum ACTIVE 35.3 37.6 -2.30 HRTX /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $53.2M $52.7M $462.7K PLRX /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR PLRX REV HRTX REV PLRX GROSS % HRTX GROSS % PLRX FCF HRTX FCF
FY 2025 $437.8M $154.9M — 73.3% -$128.7M -$27.9M
FY 2024 $639.4M $144.3M — 73.2% -$159.4M -$24.2M
FY 2023 $1.6M $309.7M — — -$116.4M -$58.8M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PLRX // BETA —
HRTX // BETA —